Impact of antiplatelet therapy on primary outcomes
| Cerebral infarction (n=379) | Major haemorrhage (n=190) | |||||||
| No at risk | Event no | aHR (95% CI) | P value | No at risk | Event no | aHR (95% CI) | P value | |
| 1–12 months | 17 692 | 141 | 0.56 (0.35 to 0.89) | 0.014 | 17 692 | 68 | 3.69 (0.89 to 15.36) | 0.072 |
| 12–24 months | 15 679 | 97 | 0.73 (0.48 to 1.12) | 0.144 | 15 750 | 39 | 1.23 (0.60 to 2.52) | 0.568 |
| >24 months | 12 333 | 141 | 1.01 (0.72 to 1.43) | 0.933 | 12 453 | 83 | 1.76 (1.11 to 2.87) | 0.016 |
Data were obtained from multivariable time-dependent Cox proportional hazards regression model for the development of outcome. The reference is the absence of APT during this period. Adjustments were made for age, sex, insurance status, hypertension, diabetes, congestive heart failure, chronic renal disease, hepatic disease, chronic obstructive lung disease, and cancer, and use of statin.
aHR, adjusted HR; APT, antiplatelet therapy.